Table 2.
Correlation of CTC status and established parameters in patients with newly diagnosed cancer
| Total | CTC positive at baseline n (%) | p value | |
|---|---|---|---|
| T stage | 0.191 | ||
| T1-2 | 6 | 0 (0%) | |
| T3 | 17 | 4 (24%) | |
| FIGO stage | 0.191 | ||
| I–II | 6 | 0 (0%) | |
| III–IV | 17 | 4 (24%) | |
| Nodal status | 0.825b | ||
| Node-negative | 8 | 1 (13%) | |
| Node-positive | 6 | 1 (17%) | |
| Unknowna | 9 | 2 (22%) | |
| Residual tumor | 0.106 | ||
| No (macroscopic complete resection) | 14 | 1 (7%) | |
| Yes | 9 | 3 (33%) | |
| Histology | 0.586 | ||
| Serous high-grade | 19 | 3 (16%) | |
| Serous low-grade | 2 | 1 (50%) | |
| Endometrioid | 1 | 0 (0%) | |
| Clear cell | 1 | 0 (0%) | |
aAccording to the national guidelines at time of surgical treatment the systematic lymphadenectomy was performed only when optimal cytoreduction has been achieved
bAnalysis performed for patients with known nodal status